Merck's ROTATEQ vaccine receives Prix Galien USA 2010 Award for Best Biotechnology Product

ROTATEQ® (Rotavirus Vaccine, Live, Oral, Pentavalent), Merck's vaccine for rotavirus gastroenteritis in infants and children, received the Prix Galien USA 2010 Award for Best Biotechnology Product, Merck announced today.

"We are honored that Merck's long-term commitment to the discovery and development of new, innovative ways to prevent and treat disease is being acknowledged with this prestigious award," said Dr. Peter S. Kim, president of Merck Research Laboratories. "We congratulate the teams whose hard work and dedication contributed to ROTATEQ."

The Prix Galien recognizes the pharmaceutical industry's outstanding achievement in the development of new medicines. An internationally recognized award, the Prix Galien was founded in France in 1969 by French pharmacist, Roland Mehl, and the 2007 ceremony was the Prix Galien's inaugural event in the United States. The Prix Galien, often considered the industry's equivalent of the Nobel Prize, is the highest accolade for pharmaceutical research and development.

The award was presented at a ceremony in New York City on Sept. 28, and follows previous Prix Galien top honors awarded to Merck in 2008 for ISENTRESS® (raltegravir) for best pharmaceutical agent.




The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
China to initiate phase 3 SARS-CoV-2 vaccine trial in UAE